Qiagen N.V. (ETR:QIA)
40.39
+0.18 (0.44%)
Sep 5, 2025, 5:35 PM CET
Qiagen Revenue
Qiagen had revenue of $533.54M USD in the quarter ending June 30, 2025, with 7.49% growth. This brings the company's revenue in the last twelve months to $2.04B, up 5.15% year-over-year. In the year 2024, Qiagen had annual revenue of $1.98B with 0.66% growth.
Revenue (ttm)
$2.04B
Revenue Growth
+5.15%
P/S Ratio
5.05
Revenue / Employee
$378.07K
Employees
5,396
Market Cap
8.77B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Qiagen News
- 5 days ago - Qiagen NV Launches QIAstat-Dx Rise: A New Era in Automated Syndromic Testing | QGEN stock news - GuruFocus
- 5 days ago - QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to ... - GuruFocus
- 5 days ago - QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing - Wallstreet:Online
- 5 days ago - QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing - Business Wire
- 9 days ago - QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds - Wallstreet:Online
- 9 days ago - QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds - Business Wire
- 10 days ago - QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds - Wallstreet:Online
- 10 days ago - QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds - Business Wire